B细胞-话题@MedSci

#B细胞#

314篇内容 | 6691人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273367, encodeId=d69f12e33672b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nature：肠道微生物影响B细胞和抗体库, objectType=article, longId=199141, objectId=9c0d19914123, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0d19914123, replyNumber=0, likeNumber=70, createdTime=2020-08-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0d19914123, moduleTitle=Nature：肠道微生物影响B细胞和抗体库, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0d19914123)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273366, encodeId=f71912e33666f, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响, objectType=article, longId=199079, objectId=eb231990e923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb231990e923, replyNumber=0, likeNumber=85, createdTime=2020-08-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb231990e923, moduleTitle=Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb231990e923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273365, encodeId=7a3d12e336511, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, objectType=article, longId=198654, objectId=e12d1986548a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12d1986548a, replyNumber=0, likeNumber=87, createdTime=2020-08-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12d1986548a, moduleTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12d1986548a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273364, encodeId=432812e3364ca, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Diabetologia：随着时间的推移，1型糖尿病缓慢进展者失去胰岛自身抗体并表现出明显的CD95hi B细胞表型？, objectType=article, longId=198182, objectId=94ab1981822a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ab1981822a, replyNumber=0, likeNumber=75, createdTime=2020-07-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ab1981822a, moduleTitle=Diabetologia：随着时间的推移，1型糖尿病缓慢进展者失去胰岛自身抗体并表现出明显的CD95hi B细胞表型？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ab1981822a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273363, encodeId=2f9e12e336385, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：采用R-CHOP治疗的原发性纵隔大B细胞淋巴瘤(PMBCL) 的预后, objectType=article, longId=197418, objectId=96e319e4187d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e319e4187d, replyNumber=0, likeNumber=101, createdTime=2020-07-14, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e319e4187d, moduleTitle=Blood：采用R-CHOP治疗的原发性纵隔大B细胞淋巴瘤(PMBCL) 的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96e319e4187d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273362, encodeId=50a612e3362b0, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, objectType=article, longId=197011, objectId=7c6419e01122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c6419e01122, replyNumber=0, likeNumber=91, createdTime=2020-07-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c6419e01122, moduleTitle=Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c6419e01122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273361, encodeId=7b3112e336198, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Exp Immunol：粪便B细胞活化因子对肠道炎症的诊断价值, objectType=article, longId=196957, objectId=85b019695ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b019695ede, replyNumber=0, likeNumber=106, createdTime=2020-07-04, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b019695ede, moduleTitle=Clin Exp Immunol：粪便B细胞活化因子对肠道炎症的诊断价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b019695ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273360, encodeId=d5fa12e3360ac, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, objectType=article, longId=196393, objectId=d7b919639342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7b919639342, replyNumber=0, likeNumber=67, createdTime=2020-06-25, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7b919639342, moduleTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7b919639342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273359, encodeId=0e2212e335947, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, objectType=article, longId=196009, objectId=77a7196009ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a7196009ec, replyNumber=0, likeNumber=66, createdTime=2020-06-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a7196009ec, moduleTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a7196009ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273358, encodeId=ca9812e33583b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, objectType=article, longId=195473, objectId=16a61954e3e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16a61954e3e1, replyNumber=0, likeNumber=97, createdTime=2020-06-09, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16a61954e3e1, moduleTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16a61954e3e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273357, encodeId=05fa12e33573f, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=CAR-T治疗复发B细胞急性淋巴细胞白血病患儿获得完全缓解, objectType=article, longId=195407, objectId=8e5719540e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e5719540e54, replyNumber=0, likeNumber=96, createdTime=2020-06-07, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e5719540e54, moduleTitle=CAR-T治疗复发B细胞急性淋巴细胞白血病患儿获得完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e5719540e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273356, encodeId=819a12e33560b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , objectType=article, longId=195309, objectId=a2e71953094c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e71953094c, replyNumber=0, likeNumber=121, createdTime=2020-06-06, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e71953094c, moduleTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e71953094c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273355, encodeId=026e12e3355cb, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, objectType=article, longId=194692, objectId=93bf194692fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93bf194692fc, replyNumber=0, likeNumber=109, createdTime=2020-05-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93bf194692fc, moduleTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93bf194692fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：E3连接酶UBR5突变调控淋巴瘤B细胞成熟, objectType=article, longId=193441, objectId=7b7a1934410d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7a1934410d, replyNumber=0, likeNumber=147, createdTime=2020-05-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7a1934410d, moduleTitle=Blood：E3连接酶UBR5突变调控淋巴瘤B细胞成熟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7a1934410d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273353, encodeId=108112e335383, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, objectType=article, longId=193101, objectId=1e4d193101ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4d193101ba, replyNumber=0, likeNumber=96, createdTime=2020-04-30, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4d193101ba, moduleTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4d193101ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Allergy：过敏性鼻炎中CD23的表达建立T-B细胞互作 , objectType=article, longId=192430, objectId=d3c6192430ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3c6192430ea, replyNumber=0, likeNumber=64, createdTime=2020-04-19, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3c6192430ea, moduleTitle=Allergy：过敏性鼻炎中CD23的表达建立T-B细胞互作 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3c6192430ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273351, encodeId=b34212e335144, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展, objectType=article, longId=191606, objectId=a4ff1916061e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4ff1916061e, replyNumber=0, likeNumber=101, createdTime=2020-04-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4ff1916061e, moduleTitle=BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4ff1916061e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273350, encodeId=d77212e335069, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, objectType=article, longId=191470, objectId=27641914e046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27641914e046, replyNumber=0, likeNumber=83, createdTime=2020-04-06, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27641914e046, moduleTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27641914e046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273349, encodeId=764412e3349d8, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Death Dis：肿瘤微环境浸润B细胞通过IL-1β/HIF-2α/ Notch1信号促进肾癌转移, objectType=article, longId=190441, objectId=8ef8190441e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ef8190441e0, replyNumber=0, likeNumber=91, createdTime=2020-03-21, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ef8190441e0, moduleTitle=Cell Death Dis：肿瘤微环境浸润B细胞通过IL-1β/HIF-2α/ Notch1信号促进肾癌转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ef8190441e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273348, encodeId=fe0c12e334877, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Death & Disease：肿瘤驯化的B细胞能够促进肾癌的转移 , objectType=article, longId=190410, objectId=1c0919041072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c0919041072, replyNumber=0, likeNumber=107, createdTime=2020-03-21, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c0919041072, moduleTitle=Cell Death & Disease：肿瘤驯化的B细胞能够促进肾癌的转移 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c0919041072)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nature：肠道微生物影响B细胞和抗体库

2020-08-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响

2020-08-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤

2020-08-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Diabetologia：随着时间的推移，1型糖尿病缓慢进展者失去胰岛自身抗体并表现出明显的CD95hi B细胞表型？

2020-07-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：采用R-CHOP治疗的原发性纵隔大B细胞淋巴瘤(PMBCL) 的预后

2020-07-14

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin cancer research：EPZ-6438联合R-CHOP治疗弥漫性大B细胞淋巴瘤

2020-07-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Exp Immunol：粪便B细胞活化因子对肠道炎症的诊断价值

2020-07-04

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO

2020-06-25

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效

2020-06-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效

2020-06-09

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

CAR-T治疗复发B细胞急性淋巴细胞白血病患儿获得完全缓解

2020-06-07

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析

2020-06-06

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致

2020-05-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：E3连接酶UBR5突变调控淋巴瘤B细胞成熟

2020-05-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率

2020-04-30

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Allergy：过敏性鼻炎中CD23的表达建立T-B细胞互作

2020-04-19

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展

2020-04-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND

2020-04-06

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Death Dis：肿瘤微环境浸润B细胞通过IL-1β/HIF-2α/ Notch1信号促进肾癌转移

2020-03-21

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Death & Disease：肿瘤驯化的B细胞能够促进肾癌的转移

2020-03-21

科室
- - 订阅+
  - 更多科室
工具
服务